Lannett Company Inc (NYSE: LCI), a company that develops, manufactures, packages, markets and distributes generic pharmaceutical products, has signed a contract with Elite Pharmaceuticals and SunGen Pharma to be the exclusive United States distributor of a generic version of Adderall, it was reported yesterday.
Adderall is an immediate-release mixed salt of a single entity Amphetamine tablet product (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate), with strengths of 5 mg, 7.5 mg, 10mg, 12.5mg, 15mg, 20mg and 30mg tablets. It is a central nervous system stimulant, indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy.
According to the contract, Lannett will mainly offer sales, marketing and distribution support for the product, for which it will receive a share of the profits. Other financial terms were not revealed.
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference